Loading clinical trials...
Loading clinical trials...
A Phase III Study in Subjects With Relapsing Forms of Multiple Sclerosis (RMS) to Asses Efficacy, Safety and Tolerability of GA Depot, a Long Acting IM Injection of Glatiramer Acetate, Once Monthly Compared to Placebo
Conditions
Interventions
GA Depot
Placebo
Locations
112
United States
Mapi Pharma Research site 08
Birmingham, Alabama, United States
Mapi Pharma Research site 11
Cullman, Alabama, United States
Mapi Pharma Research site 15
Pasadena, California, United States
Mapi Pharma Research site 14
Denver, Colorado, United States
Mapi Pharma Research site 12
Washington D.C., District of Columbia, United States
Mapi Pharma Research site 17
Homestead, Florida, United States
Start Date
September 19, 2019
Primary Completion Date
June 13, 2023
Completion Date
June 13, 2023
Last Updated
December 1, 2023
NCT05359653
NCT06390930
NCT03401879
NCT06389968
NCT05834855
NCT06413602
Lead Sponsor
Mapi Pharma Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions